Skip to content

Transcranial Alternating Current Stimulation Prevents Delirium in Patients With Subarachnoid Hemorrhage

Clinical Study of Transcranial Alternating Current Stimulation in the Prevention of Delirium in Patients With Subarachnoid Hemorrhage

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06375408
Acronym
TACS
Enrollment
74
Registered
2024-04-19
Start date
2024-03-24
Completion date
2026-03-24
Last updated
2024-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subarachnoid Hemorrhage

Keywords

Subarachnoid Hemorrhage, transcranial alternating current stimulation, delirium, Sleep quality

Brief summary

The goal of this clinical trial is to learn about using the latest transcranial alternating current stimulation (tACS) to reduce the incidence of delirium in patients with subarachnoid hemorrhage. The main question it aims to answer is: • To evaluate the effect of tACS on reducing delirium in patients with subarachnoid hemorrhage. Participants will treated with real tACS or sham tACS. Researchers will mainly compare the two groups to see if patients' delirium will reduce by using tACS.

Detailed description

Research objectives: To reduce the incidence of delirium in patients with subarachnoid hemorrhage by using the latest transcranial alternating current stimulation. Research contents: 1. To evaluate the effect of transcranial alternating current stimulation on improving sleep quality in patients with subarachnoid hemorrhage; 2. To evaluate the effect of transcranial alternating current stimulation on reducing delirium in patients with subarachnoid hemorrhage. Research hypothesis: Transcranial alternating current stimulation can improve sleep quality and reduce the incidence of delirium in patients with subarachnoid hemorrhage. Study design: 1. double-blind randomized clinical trial 2. Subjects:Patients with subarachnoid hemorrhage admitted to the neurosurgical intensive care unit during the study period. 3. Number of participating centers and names of centers: Single research center, Xuanwu Hospital, Beijing 4. Sample size: The total number of plans was 74, and the total number of study centers was 74. 5. Grouping of subjects:The random number table method was used for randomization, and the envelope method was used for randomization. The random serial number was stored in an airtight envelope, a patient was admitted, and an envelope was opened. 6. Intervention measures: ① The control group was treated with sham transcranial electrical stimulation; ② The experimental group was treated with real transcranial electrical stimulation. 7. Outcome measures: ① Efficacy indicators: the incidence and duration of delirium; The scores of Richard Campell sleep questionnaire, Hamilton Anxiety Scale, Mini-Mental State Examination, numerical rating scale for pain and muscle strength were recorded.② Safety indicators: the incidence of adverse reactions.

Interventions

DEVICEReal transcranial alternating electrical stimulation

The patients in the intervention group were treated with real tACS produced by Nexalin company. There were 3 treatment sites. According to the international 10-20 EEG system positioning method, one electrode was placed in the prefrontal lobe (Fp1, Fpz, Fp2 area, electrode size was 4.45cm×9.53cm), and the other two electrodes were placed in the left and right mastoid respectively (electrode size was 3.18cm×3.81cm). The treatment parameters were 40min twice daily with an interval of ≥4 hours for a total of 8 sessions over 4 days. tACS procedures were performed by trained and qualified full-time therapeutic nurses.

DEVICESham transcranial alternating electrical stimulation

The patients in the control group were treated with sham tACS produced by Nexalin company. The fake tACS does not emit current, so it does not stimulate the cerebral cortex. The appearance, button, electrode, and quality of the fake tACS are exactly the same as those of the real tACS in patients' senses. There were 3 treatment sites. According to the international 10-20 EEG system positioning method, one electrode was placed in the prefrontal lobe (Fp1, Fpz, Fp2 area, electrode size was 4.45cm×9.53cm), and the other two electrodes were placed in the left and right mastoid respectively (electrode size was 3.18cm×3.81cm). The treatment parameters were 40min twice daily with an interval of ≥4 hours for a total of 8 sessions over 4 days. tACS procedures were performed by trained and qualified full-time therapeutic nurses.

Sponsors

Xuanwu Hospital, Beijing
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

The random number table method was used for randomization, and the envelope method was used for randomization. The random serial number was stored in an airtight envelope, an envelope was opened when a patient was admitted.

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Subarachnoid hemorrhage was consistent with the Chinese Guidelines for the Diagnosis and Treatment of Subarachnoid Hemorrhage 2015; * Patients after completion of surgical treatment; * over 18 years of age; * Hunt & Hess grade I-III; * No major organ failure; * The patient has no speech or hearing impairment; * Informed consent of patients and their families, signed informed consent.

Exclusion criteria

* Those who have delirium at the time of enrollment; * had substance abuse/dependence within 6 months before enrollment; * had suffered from other mental illness within 6 months before enrollment; * Suffering from serious or unstable organic diseases; * Pregnant or lactating women and those planning to become pregnant in the near future; * Damaged skin integrity at the electrode placement site, allergic to electrode gels or adhesives. * with an implanted electronic stimulator; * Patients who had received other noninvasive neuromodulation therapy within 1 month before enrollment; * Participants in any other clinical trial within 1 month prior to baseline; * There are circumstances in which the researcher considers it inappropriate to participate in this study.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of deliriumup to 5days(occurrence of delirium was assessed 3 times a day from the start of the intervention to the day after the intervention ended ) Delirium incidence = Number of people who had experienced delirium within 5 days/total number of people in the intervention or control group.

Secondary

MeasureTime frameDescription
Duration of deliriumup to 5daysThe duration of patients' delirium from onset to end.
Sleep quality scoreup to 5daysThe Richard Campell Sleep Questionnaire (RCSQ) consists of five sleep-related items: sleep depth, sleep fall, wake up during sleep, fall back to sleep, and overall sleep quality. A visual analog scale was used to score the patients, with each score ranging from 0 to 100. The average score of 5 sleep-related items was calculated, with 0 to 25 being low-quality sleep and 76 to 100 being high-quality sleep.
Anxiety scoreup to 5daysHamilton Anxiety Scale (HAMA), which has 14 items, adopts a 5-level scoring method ranging from 0 to 4 points. The total score is the sum of the scores of 14 items, and the total score is \>29 points, which may be severe anxiety. \>21 points, there must be obvious anxiety; \>14 points, there must be anxiety; More than 7 points, may have anxiety; If the score is less than 7, there is no anxiety symptom.
Cognitive function scoreup to 5daysmini-mental state examination (MMSE) : There are 30 items in the scale, each item is 1 point, one correct answer will get 1 point, the full score is 30 points, the higher the score, the better the cognitive function: MMSE≥27 is classified as normal, 21-26 as mild dementia, 10-20 as moderate dementia, and \< 10 as severe dementia. MMSE is susceptible to the influence of education level, according to the level of education, its boundary standards are illiterate ≤17 points, primary school ≤20 points, secondary school or above education ≤24 points, indicating dementia.

Countries

China

Contacts

Primary ContactJun Wang, master
wangj229@126.com+86-010-83922775

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026